Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold shares of the company's common stock totaling approximately $1,047,303 across several transactions in mid-November 2026. The sales were part of a series of transactions that also included the exercise of stock options.
On November 11, Rubinstein sold 4,983 shares at prices ranging from $29.91 to $30.83, and an additional 6,898 shares at prices between $30.96 and $31.63. The following day, November 12, she disposed of 11,881 shares, with prices ranging from $28.74 to $29.73. On November 13, another 11,466 shares were sold at prices ranging from $28.43 to $29.31. The reported weighted average prices for these sales ranged from $28.93 to $31.22.
The sales come as ADPT shares trade near their 52-week high of $32.21, with the stock delivering a 106% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. The company's shares have shown significant volatility, with a beta of 2.15, as detailed in one of 11 additional ProTips available to subscribers.
Concurrently, Rubinstein acquired shares through the exercise of stock options. On November 11, she acquired 11,881 shares at an exercise price of $12.14 per share. She acquired another 11,881 shares on November 12 at the same $12.14 exercise price, and 11,466 shares on November 13, also at $12.14 per share. These option exercises totaled approximately $427,667. The options were fully vested and exercisable.
All reported transactions were executed under a Rule 10b5-1 trading plan, which Rubinstein adopted on November 18, 2025.
In other recent news, Adaptive Biotechnologies reported a significant increase in its third-quarter revenue for 2026. The company announced that its revenue rose by 39% compared to the same period last year, reaching $83.9 million. This figure surpassed Wall Street analysts' expectations, which had forecasted revenue of $71.57 million. The strong revenue performance also contributed to Adaptive Biotechnologies achieving total-company profitability earlier than anticipated.
The positive earnings report is a notable development for investors and analysts alike. While the company's stock price reacted positively in after-hours trading, the focus remains on the substantial revenue growth and early profitability. These recent developments highlight Adaptive Biotechnologies' strong financial performance in the third quarter.